Neuberger Berman Group LLC decreased its position in SPDR S&P Biotech (NYSEARCA:XBI) by 24.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,360 shares of the exchange traded fund’s stock after selling 1,100 shares during the quarter. Neuberger Berman Group LLC’s holdings in SPDR S&P Biotech were worth $259,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Wechter Feldman Wealth Management Inc. grew its holdings in SPDR S&P Biotech by 0.4% in the 2nd quarter. Wechter Feldman Wealth Management Inc. now owns 3,172 shares of the exchange traded fund’s stock valued at $245,000 after buying an additional 12 shares during the period. Willingdon Wealth Management grew its holdings in SPDR S&P Biotech by 1.8% in the 2nd quarter. Willingdon Wealth Management now owns 6,541 shares of the exchange traded fund’s stock valued at $505,000 after buying an additional 118 shares during the period. Bank of New York Mellon Corp grew its holdings in SPDR S&P Biotech by 1.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,274 shares of the exchange traded fund’s stock valued at $1,488,000 after buying an additional 197 shares during the period. Benjamin F. Edwards & Company Inc. grew its holdings in SPDR S&P Biotech by 4.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 8,692 shares of the exchange traded fund’s stock valued at $671,000 after buying an additional 346 shares during the period. Finally, FineMark National Bank & Trust grew its holdings in SPDR S&P Biotech by 7.4% in the 2nd quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock valued at $402,000 after buying an additional 360 shares during the period.

Shares of SPDR S&P Biotech (NYSEARCA XBI) opened at 84.25 on Tuesday. The firm has a 50-day moving average price of $79.74 and a 200 day moving average price of $74.23. SPDR S&P Biotech has a 12-month low of $53.15 and a 12-month high of $85.68.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 25th. Investors of record on Monday, September 18th were paid a $0.037 dividend. This represents a $0.15 annualized dividend and a yield of 0.18%. The ex-dividend date of this dividend was Friday, September 15th.

TRADEMARK VIOLATION WARNING: “Neuberger Berman Group LLC Has $259,000 Position in SPDR S&P Biotech (XBI)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/26/neuberger-berman-group-llc-has-259000-position-in-spdr-sp-biotech-xbi.html.

SPDR S&P Biotech Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.